Galmed Pharmaceuticals Ltd. (GLMD): Price and Financial Metrics
GET POWR RATINGS... FREE!
GLMD Stock Price Chart Interactive Chart >
GLMD Price/Volume Stats
| Current price | $0.65 | 52-week high | $1.84 |
| Prev. close | $0.67 | 52-week low | $0.29 |
| Day low | $0.65 | Volume | 52,600 |
| Day high | $0.72 | Avg. volume | 168,944 |
| 50-day MA | $0.50 | Dividend yield | N/A |
| 200-day MA | $0.56 | Market Cap | 16.33M |
Galmed Pharmaceuticals Ltd. (GLMD) Company Bio
Galmed Pharmaceuticals Ltd., a clinical-stage biopharmaceutical company, focuses on the development of therapeutics for the treatment of liver diseases. The company was founded in 2000 and is based in Tel Aviv, Israel.
Latest GLMD News From Around the Web
Below are the latest news stories about GALMED PHARMACEUTICALS LTD that investors may wish to consider to help them evaluate GLMD as an investment opportunity.
Can Galmed Pharmaceuticals (NASDAQ:GLMD) Afford To Invest In Growth?We can readily understand why investors are attracted to unprofitable companies. For example, biotech and mining... |
Why Enovix Shares Are Trading Lower By 43%? Here Are Other Stocks Moving In Wednesday''s Mid-Day SessionGainers Vivos Therapeutics, Inc. (NASDAQ: VVOS ) shares surged 204% to $2.25 after the company announced it received FDA 510(k) clearance for its DNA oral appliance for the treatment of obstructive sleep apnea. Crown ElectroKinetics Corp. (NASDAQ: CRKN ) climbed 162% to $0.4909 after the company announced it acquired Amerigen 7. Cryptyde, Inc. (NASDAQ: TYDE ) gained 108% to $0.4022. Geron Corporation (NASDAQ: GERN ) shares jumped 53.3% to $3.6800 after the company announced top-line results from the IMerge Phase 3 trial of imetelstat in lower risk MDS. The trial met the primary 8-week transfusion independence (TI) endpoint and key secondary 24-week TI endpoint. Shift Technologies, Inc. (NASDAQ: SFT ) rose 49% to $0.2350. Neptune Wellness Solutions Inc. (NASDAQ: NEPT ) jumped 42.4% to $0... |
Galmed reports results from the Open-Label part of the ARMOR study showing improvements in histology, imaging, and biomarkers with AramcholHistological improvement in fibrosis (≥1 stage) was demonstrated in 39% of subjects according to NASH CRN, in 61% of subjects by ranked assessment with a highly statistically significant (p<0.0001) reduction in fibrosis score demonstrated using AI-assisted, digital pathology reading Highly statistically significant (p<0.0001) reduction in liver stiffness by Fibroscan Highly statistically significant (p<0.0001) reduction in biochemical markers of liver injury ALT and AST Highly statistically significant reductions in major fibrosis biomarkers: FIB-4 (p<0.0001), Pro-C3 (p<0.0001) and ELF (p= 0.0038) at week 24 Galmed is submitting all data to the FDA to initiate discussions on incorporating more sensitive histology reading methodologies as primary endpoints in NASH clinical studies and is... |
Galmed Pharmaceuticals gets an extension from Nasdaq to regain complianceGalmed Pharmaceuticals (GLMD) received a letter from The Nasdaq, notifying the company that it is eligible for an additional 180 calendar day period, or until June 12, 2023.This… |
Galmed Pharmaceuticals Ltd. (NASDAQ: GLMD) Announces Receipt of Extension to Meet the Nasdaq''s Minimum Bid Price RequirementTEL AVIV, Israel, Dec. 14, 2022 /PRNewswire/ -- Galmed Pharmaceuticals Ltd. (Nasdaq: GLMD) ("Galmed" or the "Company"), a biopharmaceutical company focused on the development of Aramchol and Amilo-5MER, announced today that on December 13, 2022, it received a letter from The Nasdaq Stock… |
GLMD Price Returns
| 1-mo | 37.60% |
| 3-mo | 62.62% |
| 6-mo | 29.46% |
| 1-year | -53.24% |
| 3-year | -88.81% |
| 5-year | -94.06% |
| YTD | 30.00% |
| 2022 | -72.53% |
| 2021 | -41.48% |
| 2020 | -46.19% |
| 2019 | -15.37% |
| 2018 | -25.36% |
Continue Researching GLMD
Want to do more research on Galmed Pharmaceuticals Ltd's stock and its price? Try the links below:Galmed Pharmaceuticals Ltd (GLMD) Stock Price | Nasdaq
Galmed Pharmaceuticals Ltd (GLMD) Stock Quote, History and News - Yahoo Finance
Galmed Pharmaceuticals Ltd (GLMD) Stock Price and Basic Information | MarketWatch
Loading social stream, please wait...